Brief: Innovent Biologics Posts Q1 2026 Total Product Revenue Over RMB3.8 Billion
30/04/2026 02:46
April 30 (Reuters) - Innovent Biologics Inc 1801.HK: Q1 2026 TOTAL PRODUCT REVENUE EXCEEDS RMB3.8 BILLION, UP OVER 50% Y/Y Further company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis